SCHEMBL20596185

SCHEMBL20596185

COc1cc(Cl)c(-c2nccc3nc(Cc4nc5ccc(Cl)c(Cl)c5[nH]4)cn23)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MARS2 Q96GW9 4/20 0.49
▸ POLB P06746 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ MAPT P10636 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ AMY1A P0DUB6 1/20 0.31
▸ KDM4A O75164 1/20 0.31
▸ KDM5A P29375 1/20 0.31
▸ KDM5B Q9UGL1 1/20 0.31
▸ CRHR1 P34998 2/20 0.30
▸ CRH P06850 1/20 0.30
▸ KDM4E B2RXH2 2/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ PDE10A Q9Y233 1/20 0.30
▸ NOS1 P29475 1/20 0.30
▸ NOS2 P35228 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2C9 P11712 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23419328 0.86 MARS2 (0.56) MARS2POLBSMN1; SMN2MAPTRAB9A
SCHEMBL20595984 0.80 MARS2 (0.75) MARS2POLBSMN1; SMN2MAPTRAB9A
SCHEMBL23419331 0.74 MARS2 (0.44) MARS2AMY1ACRHR1
SCHEMBL20595932 0.72 MARS2 (0.40) MARS2POLBSMN1; SMN2MAPTKDM4E
SCHEMBL20596151 0.69 MARS2 (0.61) MARS2CRHR1NOS1NOS2CYP2C9
SCHEMBL30145185 0.69 MARS2 (0.61) MARS2CRHR1NOS1NOS2CYP2C9
SCHEMBL20595864 0.66 MARS2 (1.00) MARS2POLBSMN1; SMN2MAPTRAB9A
SCHEMBL20595873 0.65 MARS2 (1.00) MARS2POLBSMN1; SMN2MAPTRAB9A
SCHEMBL31253215 0.63 MARS2 (0.70) MARS2POLB
SCHEMBL27920573 0.62 GAA (0.53) MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US claimed
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON 2021-05-27 — — US disclosed
WO-2018237349-A1 INHIBITORS OF TYPED 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM UNIVERSITY OF WASHINGTON (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155617-A1 INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM AARS1, GARS1, MTR MARS2 5/4885POLB 459/4885SMN1; SMN2 1329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback